Birkenfeld, October 24, 2006
The Board of Management of STRATEC Biomedical Systems AG, which is
listed in the Prime Standard and Gate-M indices, hereby announces the
preliminary, unaudited consolidated figures based on IFRS
(International Financial Reporting Standards) of the STRATEC Group
for the first nine months of the 2006 financial year pursuant to
Section 15 of the German Securities Trading Act (WpHG).
+-------------------------------------------------------------------+
| Key Figures (EUR | 01.01.- | 01.01.- | Change |
| 000s) | 09.30.2006 | 09.30.2005 | |
|---------------------+-----------------+-----------------+---------|
| Sales | 51,933 | 33,945 | + 53.0% |
|---------------------+-----------------+-----------------+---------|
| Gross performance | 51,887 | 35,582 | + 45.8% |
|---------------------+-----------------+-----------------+---------|
| EBITDA | 8,295 | 5,315 | + 56.1% |
|---------------------+-----------------+-----------------+---------|
| EBIT | 7,199 | 4,587 | + 56.9% |
|---------------------+-----------------+-----------------+---------|
| EBT | 7,097 | 4,409 | + 61.0% |
|---------------------+-----------------+-----------------+---------|
| Consolidated net | 5,304 | 2,895 | + 83.2% |
| income | | | |
|---------------------+-----------------+-----------------+---------|
| Earnings per share | 0.48 | 0.29 | + 65.5% |
| (EUR) | | | |
+-------------------------------------------------------------------+
The STRATEC Group had a total of 215 employees as of
September 30, 2006 (previous year: 189).
Information and disclosures concerning this ad-hoc announcement:
Irrespective of possible new levels of sales and earnings correlating
with the market launch of new analyzer system families, the company
assumes that the seasonal fluctuations witnessed in sales and
earnings in the past will be increasingly countered by logistical
measures involving procurement and production.
In the past 2005 financial year, the STRATEC Group had an average of
191 employees and generated sales of Euro 47.3 million, earnings
before tax (EBT) of Euro 6.9 million and consolidated income of Euro
4.4 million, with earnings per share of Euro 0.43 (earnings for
overall previous year).
The extensive interim report will be available on our internet page
as a download from around 3 p.m. on November 8, 2006.
Based on current budgeting, the growth forecast for the company will
be reflected in particular from the second and third quarter of the
2007 financial year onwards.
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded
in the Prime Standard segment of the Frankfurt Stock Exchange, in the
Gate-M trading segment of the Stuttgart Stock Exchange and on other
exchanges.
The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",
"Robion" and "Sanguin".
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de
--- End of Ad-hoc Message ---
WKN: 728900; ISIN: DE0007289001;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in
Börse Stuttgart,
Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse
München,
Freiverkehr in Börse Düsseldorf;
Copyright © Hugin ASA . All rights reserved.